extract: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents
parent
d1061b5e65
commit
d3960afa02
4 changed files with 32 additions and 1 deletions
|
|
@ -49,6 +49,12 @@ The 92% figure applies to 'deploying, implementing, or piloting' ambient AI as o
|
|||
|
||||
WVU Medicine expanded Abridge ambient AI across 25 hospitals including rural facilities in March 2026, one month after Epic AI Charting launch. This rural expansion suggests ambient AI has passed from pilot phase to broad deployment phase, as enterprise technology typically enters academic medical centers first, then regional health systems, then rural/critical access hospitals last. The fact that a state academic health system serving one of the most rural and medically underserved states chose to expand Abridge post-Epic launch provides implicit market validation of Abridge's competitive position.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18*
|
||||
|
||||
OpenEvidence represents a second distinct clinical AI beachhead: clinical reasoning/decision support (40%+ physician adoption) separate from documentation (Abridge/ambient scribes). This creates a two-track clinical AI story where documentation automation and clinical reasoning support serve different workflows with different risk profiles and adoption dynamics. OpenEvidence's 44% physician accuracy concerns despite heavy use suggests clinical reasoning AI faces persistent trust barriers that documentation AI does not.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -17,6 +17,12 @@ What makes this significant is the adoption speed. Reaching 40% of US physicians
|
|||
|
||||
The incumbent response is UpToDate ExpertAI (Wolters Kluwer, Q4 2025), leveraging its trusted brand and install base. The competitive dynamic -- startup vs incumbent in clinical decision support -- will determine whether AI clinical knowledge becomes a winner-take-all market or fragments.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18*
|
||||
|
||||
OpenEvidence reached 20M clinical consultations/month by January 2026 (2,000%+ YoY growth from 8.5M/month in 2025), achieved 1M consultations in a single day on March 10, 2026, and is now valued at $12B (up from $3.5B, tripling in months). Used across 10,000+ hospitals nationwide. First AI to score 100% on all parts of USMLE.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -17,6 +17,12 @@ A deeper finding from a Stanford/Harvard study challenges even the "similar accu
|
|||
|
||||
The implication for AI deployment strategy: the highest-value clinical AI applications are not diagnostic augmentation but workflow automation (ambient documentation, administrative burden reduction) and safety netting (AI triage catching missed findings). The centaur model may still apply to medicine, but the interaction design must prevent physicians from overriding AI on tasks where AI demonstrably outperforms -- a politically and ethically charged constraint.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18*
|
||||
|
||||
OpenEvidence's USMLE 100% score and scale to 20M monthly physician consultations creates the first real-world test case at population scale. The absence of published outcomes data at this adoption level (40%+ of US physicians, 10,000+ hospitals) represents a critical empirical gap: if benchmark performance doesn't translate to impact, we should see evidence at this scale. The persistence of physician trust concerns (44% worried about accuracy, 19% about explainability) despite heavy use suggests users perceive limitations that benchmarks don't capture.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -7,9 +7,13 @@ date: 2026-01-01
|
|||
domain: health
|
||||
secondary_domains: [ai-alignment]
|
||||
format: company-announcement
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: medium
|
||||
tags: [openevidence, clinical-ai, decision-support, physician-adoption, clinical-decision-support, health-ai, trust]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-18
|
||||
enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -68,3 +72,12 @@ This creates a two-track clinical AI story: (1) Abridge/ambient scribes for docu
|
|||
PRIMARY CONNECTION: [[OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years]]
|
||||
WHY ARCHIVED: Significant scale update — the existing claim understates 2026 metrics by an order of magnitude. Also: USMLE 100% creates the benchmark vs. outcomes tension in practice, not theory.
|
||||
EXTRACTION HINT: Update the existing claim with scale metrics, but flag the benchmark-to-outcomes translation tension as a challenge to both the OpenEvidence claim and the benchmark performance claim
|
||||
|
||||
|
||||
## Key Facts
|
||||
- OpenEvidence valued at $12B in January 2026, up from $6B three months prior
|
||||
- 8.5M clinical consultations/month in 2025, growing to 20M/month by January 2026
|
||||
- March 10, 2026: 1M consultations in one day milestone
|
||||
- 44% of physicians concerned about accuracy and misinformation risk
|
||||
- 19% concerned about lack of physician oversight or explainability
|
||||
- Series D: $250M led by Thrive Capital and DST Global
|
||||
|
|
|
|||
Loading…
Reference in a new issue